Clinical Trial Update: Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is testing olaparib alone or in combination with atezolizumab in BRCA-mutant, non-HER2-positive breast cancer, with stages ranging from…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lynparza (olaparib)
• Tecentriq (atezolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Status: ACTIVE_NOT_RECRUITING